GSEA analysis revealed that the high expression of S100A2 was closely associated with the tumor immune microenvironment and corresponding pathways, enhanced interleukin-17 (IL-17), and tumor necrosis factor (TNF) signaling pathways, and also weakened adaptive immune response, which have been widely reported to participate in tumor progression (58–62). Here, S100A2 is linked to neoplasm.